What biomarker tests are recommended for Kidney Cancer

Biomarker Testing for Kidney Cancer

I'll walk you through the key tests recommended for kidney cancer patients, based on current clinical guidelines.

Initial Diagnostic Workup

When kidney cancer is suspected, according to the NCCN Guidelines for Kidney Cancer (Version 1.2026), your healthcare team will typically order:

Laboratory Tests

• Complete Blood Count (CBC) with differential — measures red blood cells, white blood cells, and platelets to check for anemia (low red blood cells) or other blood abnormalities
• Comprehensive Metabolic Panel — evaluates kidney function, liver function, and electrolytes
• Lactate Dehydrogenase (LDH) — an enzyme that can indicate tissue damage and is used for risk assessment
• Urinalysis — checks for blood or other abnormalities in urine

These baseline tests help your doctors understand your overall health and establish a starting point for comparison during treatment.

Tissue-Based Biomarkers (From Biopsy)

If a biopsy is performed, pathologists examine the cancer cells for:

Histology Type (Cancer Cell Appearance)

This is the most important initial biomarker:

• Clear cell RCC — the most common type (~70-80% of cases), generally has more treatment options
• Non-clear cell RCC — includes papillary, chromophobe, and other subtypes, which may require different treatment approaches

Grade

The Fuhrman grade (1-4) describes how abnormal the cancer cells look under the microscope. Higher grades suggest more aggressive cancer.

Specialized Testing for Advanced Disease

According to NCCN Guidelines, if you have advanced or metastatic kidney cancer, your team may recommend:

Imaging-Based Biomarkers

• CT or MRI with contrast — standard imaging to stage disease and detect spread
• Chest CT — preferred over chest X-ray to detect lung metastases
• FDG-PET scanning — useful in specific circumstances, particularly for:
  • Fumarate hydratase (FH)-deficient RCC
  • SDHB-deficient RCC
  • Bone-predominant disease
  • Assessment before metastasectomy (surgical removal of metastases)

Genetic/Molecular Testing Considerations

According to NCCN Guidelines, genetic evaluation should be considered if you:

• Are ≤46 years old at diagnosis
• Have multiple renal masses
• Have a family history of kidney cancer

This helps identify hereditary kidney cancer syndromes that may affect treatment and surveillance strategies.

Why These Tests Matter

For Treatment Planning: The combination of histology type, grade, and stage helps your oncologist determine which systemic therapies (immunotherapy, targeted therapy, or combinations) are most likely to work for your specific cancer.

For Prognosis: Tests like LDH and imaging findings help classify you into risk groups (favorable, intermediate, or poor risk), which guides treatment selection according to NCCN Guidelines.

For Monitoring: Baseline lab values and imaging provide comparison points to assess how well treatment is working.

Questions to Ask Your Healthcare Team

1. "What type and grade of kidney cancer do I have, and what does that mean for my treatment options?"
2. "Do I need genetic testing based on my age or family history?"
3. "Which biomarkers from my tests will be most important for deciding my treatment?"
4. "Will my biomarkers be retested during or after treatment to monitor response?"
5. "Are there any clinical trials that match my specific biomarker profile?"

Important Note

Not every patient needs every test listed here. Your oncologist will determine which specific biomarkers and tests are most relevant based on your individual situation, stage of disease, and treatment plan. The NCCN Guidelines emphasize that testing should be individualized to your clinical needs.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.